30 November 2018 - AbbVie announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. 

Under the terms of the agreements, AbbVie will grant Pfizer a non-exclusive license on specified dates to AbbVie's intellectual property relating to Humira in the United States and in various other countries around the world in which AbbVie has intellectual property:

• Pfizer's U.S. license will begin on 20 November 2023, and will not be accelerated by the entry of companies who have already taken a license.
  
• In the European Union, Pfizer can launch upon approval from the European Medicines Agency.
  

Read AbbVie press release